Private company

Rain Oncology Inc.

American pharmaceutical preparations company, incorporated in Delaware1

In its 2023 annual report the company says: “We are a late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients we believe will most likely benefit. Our lead product candidate, milademetan (also known as RAIN-32) is an oral, small molecule inhibitor of the p53-mouse double minute 2 (p53-MDM2) complex that reactivates p53.”47 It is headquartered in Newark, California.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersNewark, California1
  • Incorporated inDE2
  • Business address8000 Jarvis Avenue, Suite 204, Newark, Ca 945602
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income34-$77.1M in 2022+307% since 2020
-$80.0M-$60.0M-$40.0M-$20.0M02020: -$19.0M-$19.0M20202021: -$51.5M-$51.5M2021+172%2022: -$77.1M-$77.1M2022+50%
Net income34-$75.7M in 2022+259% since 2020
-$80.0M-$60.0M-$40.0M-$20.0M02020: -$21.1M-$21.1M20202021: -$51.4M-$51.4M2021+144%2022: -$75.7M-$75.7M2022+47%
Fiscal year20192020202120222023
Research and development$15.4M3$40.8M4$61.4M4
Operating expenses$51.5M4$77.1M4
Operating income-$19.0M3-$51.5M4-$77.1M4
Income before tax-$51.4M4-$75.7M4
Income tax$2.0K4$3.0K4
Net income-$21.1M3-$51.4M4-$75.7M4
Earnings per share-$2.654-$2.714
Earnings per share (diluted)-$2.654-$2.714
Shares (weighted, basic)19.4M shares428.0M shares4
Shares (weighted, diluted)19.4M shares428.0M shares4

Compare Rain Oncology Inc. with another company

Corporate structure

Rain Oncology Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Rain Oncology Inc.

  • PERCEPTIVE ADVISORS LLC Filed SC 13G/A on Rain Oncology Inc., latest Feb 14, 2024 (3 filings since Feb 14, 2022)
  • Samsara BioCapital, L.P. Filed SC 13G/A on Rain Oncology Inc., latest Feb 14, 2024 (2 filings since Feb 14, 2023)
  • ADAGE CAPITAL PARTNERS GP, L.L.C. Filed SC 13G/A on Rain Oncology Inc., latest Feb 7, 2024 (2 filings since Jan 30, 2023)
  • TANG CAPITAL PARTNERS LP Filed SC 13D/A on Rain Oncology Inc., latest Feb 2, 2024 (3 filings since Jun 1, 2023)
  • BIOTECHNOLOGY VALUE FUND L P Filed SC 13D/A on Rain Oncology Inc., latest Jan 29, 2024 (5 filings since Jan 11, 2022)
  • Avanish Vellanki Filed SC 13D/A on Rain Oncology Inc., latest Dec 20, 2023
  • Boxer Capital, LLC Filed SC 13D/A on Rain Oncology Inc., latest Dec 18, 2023 (3 filings since Nov 8, 2022)
  • BML Investment Partners, L.P. Filed SC 13G on Rain Oncology Inc., latest Nov 24, 2023
  • James E. Flynn Filed SC 13G/A on Rain Oncology Inc., latest May 10, 2023 (2 filings since Nov 18, 2022)
  • Cormorant Global Healthcare Master Fund, LP Filed SC 13G/A on Rain Oncology Inc., latest Feb 14, 2023 (2 filings since Feb 14, 2022)
  • Rain Oncology Inc. Newark, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Rain Oncology Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$329.0K4 Dec 31, 2022$321.0K4 Dec 31, 2021+2.5%
Accumulated depreciation$236.0K4 Dec 31, 2022$156.0K4 Dec 31, 2021+51.3%
Property and equipment, net$93.0K4 Dec 31, 2022$165.0K4 Dec 31, 2021−43.6%
Operating-lease assets (leased space)$258.0K4 Dec 31, 2022$386.0K4 Dec 31, 2021−33.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$62.0M4 Dec 31, 2022$24.8M4 Dec 31, 2021+150.0%
Marketable securities, current$68.5M4 Dec 31, 2022$115.4M4 Dec 31, 2021−40.7%
Debt securities available for sale$68.5M4 Dec 31, 2022$115.4M4 Dec 31, 2021−40.7%

Leadership

Who has led Rain Oncology Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Avanish Vellanki2021–2024

Chair

  1. Avanish Vellanki2022–2024

President

  1. Avanish Vellanki2021–2022
2025
Board members and other officers (14)

Former names

  • Rain Therapeutics Inc.Dec 13, 2017 to Dec 29, 20222

Timeline

  1. Jan 26, 20248-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights22
  2. Jan 19, 20248-K Other events23
  3. Dec 14, 20238-K Entered a material agreement; Regulation FD disclosure24
  4. Nov 9, 20238-K Results of operations25
  5. Aug 10, 20238-K Results of operations26
  6. Jun 5, 20238-K Exit or restructuring costs; Executive or director change; Shareholder vote27
  7. May 22, 20238-K Regulation FD disclosure28
  8. May 11, 20238-K Results of operations29
  9. Mar 10, 20238-K Regulation FD disclosure30
  10. Mar 9, 20238-K Results of operations31
  11. Feb 22, 20238-K Bylaws or fiscal year changed32
  12. Feb 9, 20238-K Other events33
  13. Apr 22, 2021New chief executive Avanish Vellanki becomes CEO7

Calendar

When it reported results

  1. Nov 9, 2023Reported quarterly or annual results25
  2. Aug 10, 2023Reported quarterly or annual results26
  3. May 11, 2023Reported quarterly or annual results29
  4. Mar 9, 2023Reported quarterly or annual results31
  5. Nov 14, 2022Reported quarterly or annual results34
  6. Mar 3, 2022Reported quarterly or annual results35
  7. Nov 10, 2021Reported quarterly or annual results36

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

140 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 20 major events, 55 insider forms, 24 large holders, 32 other. The latest 20:

  1. Feb 14, 2024SC 13G/A EDGAR
  2. Feb 14, 2024SC 13G/A EDGAR
  3. Feb 7, 2024SC 13G/A RAIN ONCOLOGY, INC. EDGAR
  4. Feb 5, 202415-12G NOTICE OF TERMINATION OF REGISTRATION OF A CLASS OF SECURITIES EDGAR
  5. Feb 2, 20244 EDGAR
  6. Feb 2, 2024SC 13D/A AMENDMENT NO. 2 EDGAR
  7. Jan 30, 2024EFFECT EDGAR
  8. Jan 29, 20244 EDGAR
  9. Jan 29, 2024SC 13D/A AMENDMENT NO. 8 TO SCHEDULE 13D EDGAR
  10. Jan 26, 2024S-8 POS POST-EFFECTIVE AMENDMENT TO A S-8 EDGAR
  11. Jan 26, 2024S-8 POS POST-EFFECTIVE AMENDMENT TO A S-8 EDGAR
  12. Jan 26, 2024S-8 POS POST-EFFECTIVE AMENDMENT TO A S-8 EDGAR
  13. Jan 26, 20244 EDGAR
  14. Jan 26, 20244 EDGAR
  15. Jan 26, 20244 EDGAR
  16. Jan 26, 20244 EDGAR
  17. Jan 26, 20244 EDGAR
  18. Jan 26, 20244 EDGAR
  19. Jan 26, 20244 EDGAR
  20. Jan 26, 20244 EDGAR

The 140 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

22 open-market trades by officers, directors and large owners since October 2021: 14 buys and 8 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 18, 2023TANG CAPITAL PARTNERS LP10% ownerSale40,132$1.21$48.6KForm 4
Dec 15, 2023TANG CAPITAL PARTNERS LP10% ownerSale109,435$1.20$131.3KForm 4
Dec 14, 2023TANG CAPITAL PARTNERS LP10% ownerSale24,406$1.21$29.5KForm 4
Oct 13, 2023TANG CAPITAL MANAGEMENT LLC10% ownerBuy131,631$0.99$130.3KForm 4
Oct 12, 2023TANG CAPITAL MANAGEMENT LLC10% ownerBuy77,702$0.98$76.1KForm 4
Oct 11, 2023TANG CAPITAL MANAGEMENT LLC10% ownerBuy74,812$0.97$72.6KForm 4
Jun 1, 2023TANG CAPITAL MANAGEMENT LLC10% ownerBuy333,325$1.11$370.5KForm 4
May 31, 2023TANG CAPITAL MANAGEMENT LLC10% ownerBuy166,180$1.08$179.6KForm 4
May 30, 2023TANG CAPITAL MANAGEMENT LLC10% ownerBuy588,768$1.03$608.7KForm 4
May 22, 2023Boxer Capital, LLCDirectorSale995,000$1.25$1.2MForm 4
Nov 22, 2022BERGER FRANKLIN MDirectorBuy77,000$8.27$636.8KForm 4
Nov 21, 2022BERGER FRANKLIN MDirectorBuy45,000$7.80$351.0KForm 4
Nov 8, 2022BVF II GP LLCDirectorBuy1,710,358$5.83$10.0MForm 4
Nov 8, 2022BERGER FRANKLIN MDirectorBuy42,881$5.83$250.0KForm 4
Nov 4, 2022Davis Aaron I.DirectorBuy972,212$5.83$5.7MForm 4
Jun 1, 2022Vellanki AvanishChairman and CEOBuy25,000$2.29$57.2KForm 4
Jan 7, 2022BVF INC/ILDirectorBuy496,385$12.00$6.0MForm 4
Jan 6, 2022BVF INC/ILDirectorBuy61,343$12.00$736.1KForm 4
Oct 12, 2021EDELMAN JOSEPH10% ownerSale7,306$13.40$97.9KForm 4
Oct 11, 2021EDELMAN JOSEPH10% ownerSale21,826$12.51$273.0KForm 4

All 22 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Rain Oncology Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARRain Oncology Inc.1
  • CIK0001724979
  • Employer ID (EIN)82-11309671
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address8000 Jarvis Avenue, Suite 204, Newark, CA 945601
  • Phone(510) 953-55591
  • Shares outstanding36,375,671 as of Nov 3, 20236
  • Public float$43.9M as of Jun 30, 20224
  • On EDGAR sinceDec 13, 20171
  • Filings214 in all: 4 (71), 8-K (25), 3 (17), SC 13D/A (14), 10-Q (9), SC 13G/A (8), CORRESP (6), SC 13G (6)1
    All 40 form types

    UPLOAD (6), SC 13D (4), D (3), EFFECT (3), S-8 (3), S-8 POS (3), SC 14D9/A (3), SC TO-T/A (3), 10-K (2), DEF 14A (2), DEFA14A (2), S-1/A (2), SC 14D9 (2), SEC STAFF LETTER (2), 144 (1), 15-12G (1), 25-NSE (1), 4/A (1), 424B4 (1), 424B5 (1), 8-A12B (1), ARS (1), CERT (1), DRS (1), DRS/A (1), DRSLTR (1), FWP (1), POS AM (1), S-1 (1), S-3 (1), SC TO-C (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Mar 9, 2023
    Quarterly report (10-Q) Nov 9, 2023
    Proxy statement (DEF 14A) Apr 19, 2023
    Latest 8-K (8-K) Jan 26, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
    SEC EDGAROther events
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
    SEC EDGAROther events
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47